Efficacy and safety of revefenacin for nebulization in patients withchronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA:subgroup analysis from phase III trials

摘要

Combinations of a long-acting muscarinic receptor antagonist (LAMA),long-acting β-agonist (LABA), and inhaled corticosteroid (ICS) are used forpatients with persistent chronic obstructive pulmonary disease (COPD)exacerbations on bronchodilator monotherapy. In this prespecified subgroupanalysis, we assessed the efficacy and safety of the LAMA revefenacin inpatients with COPD taking concomitant LABA, including ICS/LABA (LABAsubgroup).